Merck Sharp & Dohme LLC has prepared and tested triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of Alzheimer’s disease and neurodegeneration.

Positive late-stage study results position the company to file for clearance of what could be the first narcolepsy drug that targets orexin proteins.